



# STATE MEDICAID P&T COMMITTEE MEETING

Thursday, November 20, 2014

7:00 a.m. to 8:30 a.m.

Cannon Health Building

Room 125



## MINUTES

### Committee Members Present:

Lisa Hunt, R.Ph.

Kort Delost, R.Ph.

Elizabeth Young, Pharm.D.

Julia Ozbolt, M.D.

Jameson Rice, Pharm.D.

Roger Martenau, M.D.

Ellie Brownstein, M.D.

### Committee Members Excused:

Beth Johnson, R.Ph.

### Dept. of Health/Div. of Health Care Financing Staff Present:

Richard Sorenson, RN

Trevor Smith, CPhT

Merelynn Berrett, RN

Robyn Seely, Pharm.D.

Tim Morley, R.Ph.

Heather Santacruz, RN

### University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Cameron Hill, UofU

Gary Oderda, UofU

Christina Brown, UofU

### Other Individuals Present:

Sean McGarr, Actavis

Kyle Linhardt, Upshire-Smith

Lee Strout, Chiess USP

Cody Ball, Select Health

Don McCaffrey, Vertex

Meeting conducted by: Kort Delost

---

1. **Review and Approval of October Minutes:** Minutes for October were reviewed. Two misspelling errors were found and pending those corrections, a motion was made to approve the minutes by Julia Ozbolt. Beth Young seconded the motion. All in favor.

2. **Housekeeping:**

- a. PDL Administration: A review of 128 of the drug classes for the 2015 PDL is underway.
- b. Lisa Hunt reminded everyone to sign in and to take an agenda.

3. **Drug Utilization Review (DUR) Board update:** The DUR board reviewed rheumatoid arthritis treatments during the November meeting. The same topic will be discussed in

the December DUR meeting.

4. **Amebicide Agents:** Melissa Archer presented a review of the Amebicide agents. She presented peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines Utah Medicaid utilization data. She broke the review into two parts, anti-malarial agents and antiprotozoal agents.
5. **Public Comments:** None
6. **Committee discussion:**
  - a. Lisa Hunt presented the other States report including prior authorization requirements and preferred drug lists for the antimalarial agents.
  - b. The committee began discussing the antimalarial agents.
  - c. Julia Ozbolt asked if any of the agents require a prior authorization. The quinine (Qualaquin) is the only agent that currently requires a prior authorization looking for a diagnosis of malaria.
  - d. Kort Delost asked if hydroxychloroquine would still be payable for other diagnosis.
  - e. Lisa Hunt said that the current computer system does not look for a particular diagnosis unless it is specifically programmed.
  - f. Tim Morley asked if there are current bids for rebates in this class. Lisa Hunt responded that there are, and for this reason that class is up for review.
  - g. Julia Ozbolt asked about if a liquid agent should be preferred.
  - h. Kort Delost made a motion that the agents are equally safe and efficacious for their approved indications. He added that the hydroxychloroquine should be made a preferred agent on the PDL because of the wide usage and the usage in other indications. Jameson Rice seconded the motion. All in favor.
  - i. Lisa Hunt presented the other States report including prior authorization requirements and preferred drug lists for the antiprotozoal agents.
  - j. Kort Delost said that the committee should look at the dosage forms. It was clarified that only oral use was up for discussion, not the topical or other formulations.
  - k. Kort Delost explained about the metronidazole products and how the compounding works for the metronidazole products. He said it is difficult at times since many payors will not cover ingredients in the compound other than the active ingredient. This can make it not cost effective to the pharmacy.
  - l. The committee said that due to high usage, the oral metronidazole should be preferred, and there should be a liquid formulation or suspension preferred.
  - m. Jameson Rice made a motion that the antiprotozoal agents are equally safe and effective for their indicated uses. Ellie Brownstein seconded the motion. All in favor.
  - n. Ellie Brownstein made a motion that the oral metronidazole should be included as a preferred agent due to utilization. Julia Ozbolt seconded the motion. All in favor.
  - o. Julia Ozbolt made a motion to make nitazoxanide suspension and tablets be included as a preferred agent because this is the only treatment for cryptosporidium and is the only liquid or suspension formulation available for

children. Jameson Rice seconded the motion. All in favor.

**7. Meeting Adjourned**

8. December meeting is canceled. Next meeting is scheduled for January 15, 2015. Amebicide anti-infective agents will be discussed.
9. Lisa Hunt requested that Committee members inform her of their anticipated presence of absence so that a quorum is ensured at each meeting.

---

Minutes prepared by Trevor Smith

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)